38783756|t|Trends of use and characterisation of anti-dementia drugs users: a large multinational-network population-based study.
38783756|a|BACKGROUND: An updated time-trend analysis of anti-dementia drugs (ADDs) is lacking. The aim of this study is to assess the incident rate (IR) of ADD in individuals with dementia using real-world data. SETTING: Primary care data (country/database) from the UK/CPRD-GOLD (2007-20), Spain/SIDIAP (2010-20) and the Netherlands/IPCI (2008-20), standardised to a common data model. METHODS: Cohort study. Participants: dementia patients >=40 years old with >=1 year of previous data. Follow-up: until the end of the study period, transfer out of the catchment area, death or incident prescription of rivastigmine, galantamine, donepezil or memantine. Other variables: age/sex, type of dementia, comorbidities. Statistics: overall and yearly age/sex IR, with 95% confidence interval, per 100,000 person-years (IR per 105 PY (95%CI)). RESULTS: We identified a total of (incident anti-dementia users/dementia patients) 41,024/110,642 in UK/CPRD-GOLD, 51,667/134,927 in Spain/SIDIAP and 2,088/17,559 in the Netherlands/IPCI.In the UK, IR (per 105 PY (95%CI)) of ADD decreased from 2007 (30,829 (28,891-32,862)) to 2010 (17,793 (17,083-18,524)), then increased up to 2019 (31,601 (30,483 to 32,749)) and decrease in 2020 (24,067 (23,021-25,148)). In Spain, IR (per 105 PY (95%CI)) of ADD decreased by 72% from 2010 (51,003 (49,199-52,855)) to 2020 (14,571 (14,109-15,043)). In the Netherlands, IR (per 105 PY (95%CI)) of ADD decreased by 77% from 2009 (21,151 (14,967-29,031)) to 2020 (4763 (4176-5409)). Subjects aged >=65-79 years and men (in the UK and the Netherlands) initiated more frequently an ADD. CONCLUSIONS: Treatment of dementia remains highly heterogeneous. Further consensus in the pharmacological management of patients living with dementia is urgently needed.
38783756	38	43	anti-	Chemical	-
38783756	43	57	dementia drugs	Disease	MESH:D003704
38783756	170	184	dementia drugs	Disease	MESH:D003704
38783756	186	190	ADDs	Disease	MESH:D003704
38783756	265	268	ADD	Disease	
38783756	289	297	dementia	Disease	MESH:D003704
38783756	533	541	dementia	Disease	MESH:D003704
38783756	542	550	patients	Species	9606
38783756	680	685	death	Disease	MESH:D003643
38783756	714	726	rivastigmine	Chemical	MESH:D000068836
38783756	728	739	galantamine	Chemical	MESH:D005702
38783756	741	750	donepezil	Chemical	MESH:D000077265
38783756	754	763	memantine	Chemical	MESH:D008559
38783756	799	807	dementia	Disease	MESH:D003704
38783756	996	1004	dementia	Disease	MESH:D003704
38783756	1011	1019	dementia	Disease	MESH:D003704
38783756	1020	1028	patients	Species	9606
38783756	1172	1175	ADD	Disease	
38783756	1393	1396	ADD	Disease	
38783756	1530	1533	ADD	Disease	
38783756	1646	1649	men	Species	9606
38783756	1711	1714	ADD	Disease	
38783756	1742	1750	dementia	Disease	MESH:D003704
38783756	1836	1844	patients	Species	9606
38783756	1857	1865	dementia	Disease	MESH:D003704
38783756	Negative_Correlation	MESH:D000077265	MESH:D003704
38783756	Negative_Correlation	MESH:D005702	MESH:D003704
38783756	Negative_Correlation	MESH:D000068836	MESH:D003704

